Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04148651 · ClinicalTrials.gov registry record · NA
The CO2RE® System for Vulvar Lichen Sclerosus
A NA study, sponsored by Candela Corporation.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT04148651 is a NA study that has completed, run by Candela Corporation. The registered enrollment target is 14 participants.
The verdict
NCT04148651, a NA study, has completed, sponsored by Candela Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Subjects with vulvar lichen sclerosus (VLS) will undergo fractional carbon dioxide (CO2) laser treatment to the vulvar area. Subjects will be evaluated for changes in clinical signs and architectural changes associated with VLS at designated follow-ups to 1-year post treatment series.
Interventions
- DEVICE The CO2RE® System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2020-12-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04148651
The ClinicalTrials.gov registry entry for NCT04148651 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candela Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which The CO2RE® System is the first listed.
NCT04148651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04148651 about?
NCT04148651 is a clinical study titled "The CO2RE® System for Vulvar Lichen Sclerosus". Subjects with vulvar lichen sclerosus (VLS) will undergo fractional carbon dioxide (CO2) laser treatment to the vulvar area. Subjects will be evaluated for changes in clinical signs and architectural changes associated with VLS at designated follow-ups to 1-year post treatment series.
What is the current status of trial NCT04148651?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-07-11. Estimated completion is 2020-12-17.
What interventions are being tested in trial NCT04148651?
The interventions under investigation include: The CO2RE® System (DEVICE).
Who is sponsoring clinical trial NCT04148651?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.